AUSTIN, Texas–(BUSINESS WIRE)—- $IPA #AI–ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a global leader in AI-powered antibody discovery and development, today announced a strategic collaboration with RIBOPRO, a pioneering technology provider specializing in mRNA and lipid nanoparticle (LNP) technologies. This collaboration seeks to revolutionize the discovery and development of therapeutic antibodies by integrating RIBOPRO’s advanced mRNA-based antigen expression expertise with I
发布者：Dr.Durant，转转请注明出处：https://robotalks.cn/ipa-and-ribopro-partner-to-advance-mrna-driven-antibody-discovery-unlocking-new-frontiers-in-immunotherapy/
